Table 1. Patient Demographics at the Initiation of the CAMP Posttrial Observation Perioda.
| Characteristic | ICS therapy | |
|---|---|---|
| Recommended (n=425) | Not recommended (n=489) | |
| Age, yb | 13.5 (2.3) | 13.7 (2.2) |
| Race | ||
| Black | 62 (14.6) | 64 (13.1) |
| Hispanic | 36 (8.5) | 47 (9.6) |
| Other | 35 (8.2) | 37 (7.6) |
| White | 292 (68.7) | 341 (69.7) |
| Sex | ||
| Male | 276 (64.9)c | 277 (56.6) |
| Female | 149 (35.1) | 212 (43.4) |
| Pulmonary function test resultsb | ||
| FEV1, % predicted | 92 (13)c | 99 (13) |
| FVC, % predicted | 105 (13) | 107 (12) |
| FEV1/FVC ratio | 76 (9)c | 81 (8) |
| Serum IgE level, U/mLd | 634c | 391 |
| No. of positive allergy skin test resultsd | 4 | 3 |
| Asthma status rated at CAMPCS transitione | ||
| In remission (mild) | 217 (51.1)c | 414 (84.7) |
| Moderate to severe | 190 (44.7) | 32 (6.5) |
Abbreviations: CAMP, Childhood Asthma Management Program; CAMPCS, CAMP Continuation Study; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroid.
a
Data are given as number (percentage) of each group unless otherwise indicated.
b
Data are given as mean (SD).
c
P < .05 using the χ2 test for categorical variables and the t test for continuous variables.
d
Data are given as the median.
e
Percentages do not total 100 because 61 children did not have data available on the reclassification of severity at the time of the transition.